Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 10/26/2014
‘New, significantly improved hepatitis C drugs have revolutionized how the disease is treated, but they are also expensive. One such drug, sofosbuvir, costs more than $7,000 a week for 12 weeks of treatment. That could amount to a hefty price tag for American prison systems, which house more than 500,000 people infected with hepatitis C, a chronic viral infection that causes liver damage and is spread via contact with infected blood.’
‘This month the American Journal of Public Health published an article with surprising new findings: People who inject prescription opioid analgesics (pain pills) are five times more likely to be hepatitis C infected than people who inject other drugs like heroin or cocaine.’
‘SPANIARDS infected with both HIV and the hepatitis C virus are less likely to be cured than people of other nationalities, because of their genes. Most coinfected Spanish patients are considered ‘difficult to cure’ due to their genetic makeup, according to data presented at the AASLD/ EASL Special Conference on Hepatitis C in New York.’
‘In this new era of rapidly improving cure rates for hepatitis C virus (HCV) thanks to a new generation of drugs, do we still need to stage HCV prior to therapy? Stanley M. Cohen, MD, professor of medicine and medical director of hepatology, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, began his presentation at the American College of Gastroenterology 2014 Annual Scientific Meeting and Postgraduate Course by asking whether new science should make clinicians change old ways of doing things.’
‘Regular readers of this blog probably know that the Centers for Disease Control and Prevention (CDC) recommends hepatitis C (HCV) screening for everyone in the demographic group in the U.S. that is most likely to be infected—people born between 1945 and 1965.’
‘Using hepatitis C virus (HCV) core-antigen testing to screen for acute hep C cases among HIV-positive people is reliable and saves time, money and resources when compared with polymerase chain reaction (PCR) testing. Publishing their findings in Clinical Infectious Diseases, researchers conducted a study comparing the capacity of PCR and core-antigen tests to diagnose recent HCV infections among people living with HIV.’